In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera (dimethyl fumarate) should remain invalid because the matter had already been resolved by another court.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 March 2017 A Biogen patent covering the drug Tecfidera has been upheld by the Patent Trial and Appeal Board, after a challenge from Kyle Bass’s Coalition for Affordable Drugs.
29 September 2020 The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
23 March 2017 A Biogen patent covering the drug Tecfidera has been upheld by the Patent Trial and Appeal Board, after a challenge from Kyle Bass’s Coalition for Affordable Drugs.
29 September 2020 The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
23 March 2017 A Biogen patent covering the drug Tecfidera has been upheld by the Patent Trial and Appeal Board, after a challenge from Kyle Bass’s Coalition for Affordable Drugs.
29 September 2020 The US Court of Appeals for the Federal Circuit has sided with EMD Serono and Pfizer over the invalidation of a multiple sclerosis drug patent, in a defeat for biotech company Biogen.
